Protagonist Therapeutics, Inc.

203 articles about Protagonist Therapeutics, Inc.

• Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera

  6/3/2021

   Protagonist Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV)

• 

  Protagonist, Janssen Win Breakthrough Therapy Designation for Oncology Candidates

  6/3/2021

  Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.

• Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

  5/24/2021

  Protagonist Therapeutics, Inc. announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor antagonist peptide.

• Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021

  5/12/2021

   Protagonist Therapeutics ("Protagonist" or the "Company") (Nasdaq: PTGX), today announced that an abstract highlighting updated data from its ongoing Phase 2 clinical study evaluating rusfertide irusfertide in polycythemia vera ("PV") has been selected for an oral presentation at the upcoming European Hematology Association ("EHA") 2021 Annual Congress.

• Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/4/2021

  Protagonist Therapeutics reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update.

• Protagonist Therapeutics Reports Granting of Inducement Award - May 03, 2021

  5/3/2021

  Protagonist Therapeutics, Inc. reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hired Vice President, Discovery Biology and Translational Research, in accordance with the terms of Dr. Bhatt's employment offer letter.

• Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting

  4/27/2021

  -- Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythemia vera --

• Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency

  3/22/2021

  Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration ("FDA") has provided important feedback during an End-of-Phase 2 meeting on rusfertide (PTG-300), an investigational new treatment for polycythemia vera ("PV")

• Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

  3/10/2021

  Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera

• Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

  3/3/2021

  Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET / 1:30 pm PT to discuss its fourth quarter and full year 2020 financial results. Conference Call and Webcast Information

• Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C. Wainwright Global Life Sciences Conference taking place March 9 to March 10, 2021.

• Protagonist Therapeutics Reports Granting of Inducement Award - Feb 26, 2021

  2/26/2021

  Protagonist Therapeutics, Inc. reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recently hired Vice President, Corporate Affairs, in accordance with the terms of Ms.

• Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

  2/16/2021

  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021 .

• Protagonist Therapeutics Reports Granting of Inducement Award - Jan 29, 2021

  1/29/2021

  Protagonist Therapeutics, Inc. reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. O'Connor's employment offer letter.

• Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 , at 2:00 p.m EST. A live and archived webcast of the event will be available in the Investors section o

• Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)

  12/16/2020

  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide.

• Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/15/2020

  Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its common stock

• Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

  12/11/2020

  Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of $21.00 per share.

• Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories

  12/7/2020

  Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting

• Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

  12/6/2020

  PTG-300 controlled hematocrit and reversed iron deficiency in patients receiving therapeutic phlebotomy, cytoreductive therapy or interferon